Clinical trials: Clostridioides Difficile
Inflammatory Bowel Diseases, Clostridium Difficile Infections
Research on Gut Microbiome and Metabolomics Alterations in C.Difficile Infected IBD Patients
The goal of this research is to compare alterations of gut microbiota and fecal metabolomics alterations between inflammatory bowel disease patients infected with or without Clostridioides difficile.
- Conditions
- Inflammatory Bowel Diseases, Clostridium Difficile Infections, Microtia
- Trial name
- NCT05714566
- Testing
- Clostridioides difficile toxin detection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Recurrence of Clostridium Difficile Infection
REBYOTA™ Prospective Registry
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting.
- Trial name
- ROAR (NCT05835219)
- Testing
- REBYOTA™
- Where
- 42 sites in United States
- Volunteers
- 145 people
- Sponsor
- Ferring Pharmaceuticals
Clostridium Difficile
PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol
A total of 440 patients meeting enrollment criteria with a primary episode of C. Difficile Infection (CDI) will be enrolled across 3 sites.
- Trial name
- PROCLAIM (NCT03617172)
- Testing
- Misoprostol 100Mcg Tab
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt University Medical Center
Clostridium Difficile Associated Disease
Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age
This study will investigate a Clostridium difficile vaccine in healthy adults 65 to 85 years of age, who will each receive 3 doses of vaccine.
- Trial name
- NCT03579459
- Testing
- Clostridium difficile vaccine
- Where
- 24 sites in United States
- Volunteers
- 1,317 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridium Difficile Infection
MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)
MET-2 clinical study is an Open label, single center, multiple dose pilot study of 19 patients. The study is designed to measure the resolution of diarrhea as well as the feasibility of administration and safety of MET-2 for the…
- Trial name
- NCT02865616
- Testing
- MET-2, Vancomycin
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- NuBiyota
Recurrent Clostridioides Difficile Infection, Colonic Surgery
Intestinal Microbiota Transplantation in Patients Undergoing Colon Resection
This is a single-center, open-label study for safety and feasibility of IMT in patients undergoing colonic surgery. After consent, individuals of the ages of 18-75 with a history of diverticulitis or sigmoid colon cancer will be…
- Trial name
- NCT06370884
- Testing
- IMT
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Minnesota
Diarrhea, Clostridium Infections
Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients
The purpose of this study is to evaluate the efficacy and safety of Bio-K + CL1285 versus placebo in the prevention of antibiotic-associated diarrhea in hospitalized adult patients.
- Trial name
- NCT00328263
- Testing
- Lactobacillus acidophilus CL1285 and Lactobacillus casei
- Where
- 8 sites in Canada
- Volunteers
- 472 people
- Sponsor
- Bio-K Plus International Inc.
Clostridium Difficile
Comparative Study of Three Different Testing Mechanisms for Clostridium Difficile
The purpose of this study is to establish which of the following tests perform best in diagnosing clostridium difficile. PCR, Enzyme Immunoassays (EIA) and C. difficile cytotoxin assay (CTA).
- Trial name
- NCT01066221
- Where
- Canada
- Volunteers
- 470 people
- Sponsor
- Hamilton Health Sciences Corporation
Severe Clostridium Difficile Infection, Severe-Complicated/Fulminant Clostridium Difficile Infection
Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)
This is a randomized, open label, comparative, Phase II study to determine whether fecal microbiota transplant using Penn Microbiome Therapy products helps standard therapy to treat severe Clostridium difficile infection (C diff).
- Trial name
- NCT03970200
- Testing
- Penn Microbiome Therapy - 001, Penn Microbiome Therapy - 002, Penn Microbiome Therapy - 003
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Pennsylvania
Positive C-Diff Culture
Whey Protein Concentrate 40% Made of Milk of Immunized Cows to Aid in the Prevention of Relapse of Clostridium Difficile-Diarrhea
The primary objective of this study is to assess the safety of the investigational agent, MucoMilk®, a polyclonal-antibody enriched Whey Protein Concentrate 40% (WPC-40) made of milk of immunized cows.
- Trial name
- NCT00177775
- Testing
- MucoMilk product
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Pittsburgh
Bacteria Infection Mechanism
Study of Factors Influencing the Dynamics of Colonisation and Decolonisation of the Digestive Tract by Clostridioides Difficile in Infants
Clostridioides difficile (formerly C. difficile) is a bacterium found in the form of spores (a resistant form) to which patients may be exposed in a hospital environment.
- Trial name
- BBDIFF (NCT07512908)
- Testing
- cohort follow up
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fondation Hôpital Saint-Joseph
Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin
The purpose of this study is to evaluate the ability of oral vancomycin in preventing Clostridioides difficile infection (CDI) in patients that are simultaneously receiving antibiotics.
- Trial name
- NCT07221708
- Testing
- Vancomycin (POC)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Solid Organ Transplant Complications
Washed Microbiota Transplantation in Solid Organ Transplantation
Solid organ transplantation (SOT), an alternative therapy for end-stage diseases, offers increased longevity and better quantity of life.
- Trial name
- NCT06708676
- Testing
- Washed Microbiota Transplantation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Clostridium Difficile
Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infection) in VA
Clostridium difficile (C. difficile) is a major pathogen causing serious healthcare-associated diarrheal illness in patients. Prevention of healthcare facility-onset C. difficile infection (CDI) is essential.
- Trial name
- GLORI (NCT04036058)
- Testing
- Universal gloving
- Where
- 6 sites in United States
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Clostridium Difficile Infection Recurrence
Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection
This is a research study to collect information from people that have Clostridium difficile infection (CDI) and are treated with a standard antibiotic treatment in which the antibiotic dose is gradually reduced over 6 weeks and…
- Trial name
- BEZLO (NCT03880539)
- Testing
- bezlotoxumab, Vancomycin Oral
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Kansas Medical Center
Clostridioides Difficile Infection
Addressing Personalized Needs in Clostridioides Difficile Infection
BEYOND is aiming to demonstrate how by enrichment of the available SPECIFY score, patients at great likelihood for CDI with unfavorable outcome are early detected
- Trial name
- BEYOND (NCT04725123)
- Testing
- Microbiome analysis
- Where
- Greece
- Volunteers
- 153 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Fecal Microbiota Transplantation, Clostridium Difficile Infection
Fecal Microbiota Transplant National Registry
A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness
- Conditions
- Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
- Trial name
- FMT (NCT03325855)
- Testing
- None - Observational
- Where
- 53 sites in United States, Canada
- Volunteers
- 4,000 people
- Sponsor
- American Gastroenterological Association
Enterocolitis Clostridium Difficile Recurrent
FMT Delivered by Capsule Versus Colonoscopy for Recurrent C. Diff
Delivery of FMT by upper route, including gastroscopy, nasogastric/ nasojejunal tube, and lower route, including retention enema, sigmoidoscopy, or colonoscopy have all been utilized successfully.
- Trial name
- NCT02254811
- Testing
- Fecal Microbiota Transplant
- Where
- 2 sites in Canada
- Volunteers
- 116 people
- Sponsor
- University of Alberta
Diarrhea, Clostridium Difficile
Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly
The purpose of this study is to determine whether Lactobacillus acidophilus/rhamnosus complex is effective in the prevention of antibiotic-associated diarrhea (AAD) in the elderly.
- Trial name
- NCT01048567
- Testing
- Lactobacillus acidophilus/rhamnosus
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- Vancouver Island Health Authority
Clostridioides Difficile Infection
Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection
The purpose of this research is to evaluate the primary objectives of safety and efficacy (rate of clinical cure) of 2 dosages of CRS3123 (200 mg and 400 mg) administered orally (po) twice daily (bid) and vancomycin administered…
- Trial name
- NCT04781387
- Testing
- CRS3123, Active Comparator
- Where
- 20 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- Crestone, Inc